Clinical Trial Update: Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma [NA]

View source ↗

Summary

A clinical trial evaluating fludarabine and cyclophosphamide followed by LMB-2 immunotoxin for Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• LMB-2 immunotoxin (LMB-2 immunotoxin)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Lymphoma | NA | Status: WITHDRAWN